据"证监会发布"11月28日消息，安徽证监局严肃查处立方数科严重财务造假案件。 以下为原文： 近日，证监会对上市公司立方数科股份有限公司（简称立方数科）涉嫌定期报告财务数据存在虚假记载作出行政处罚及市场禁入事 先告知。 经查，2021年至2023年，立方数科通过开展代理业务、融资性贸易、虚假贸易等方式，累计虚增收入6.38亿元、成本6.28亿元。其 中，2021年收入、成本分别虚增2.80亿元、2.77亿元，2022年收入、成本分别虚增3.12亿元、3.05亿元，2023年收入、成本分别虚增 0.46亿元、0.45亿元。立方数科连续三年虚增收入和成本，严重违反证券法律法规，安徽证监局拟对立方数科处以1000万元罚款， 对汪逸等10名责任人合计罚款3000万元。立方数科涉嫌触及重大违法强制退市情形，深交所将依法启动退市程序。 同时，我会决定对本案所涉会计师事务所执业行为正式立案调查，涉嫌未能勤勉尽责的将依法严惩。对于相关违法行为可能涉及的 证券犯罪问题线索，我会将坚持应移尽移的工作原则，依法依规移送公安机关。 11月28日，立方数科（300344）发布关于公司股票将被实施退市风险警示暨股票停复牌的公告。 公告称 ...

Core Viewpoint - ST Lifan is facing severe financial fraud allegations, which may lead to its delisting from the stock market due to continuous financial misconduct from 2021 to 2023 [4][10]. Group 1: Regulatory Actions - The China Securities Regulatory Commission (CSRC) has issued a notice of administrative punishment against ST Lifan for false reporting of financial data [6]. - The Anhui Securities Regulatory Bureau plans to impose a total fine of 40 million yuan on ST Lifan and related responsible individuals [4]. - The company is under investigation for significant violations that could trigger mandatory delisting procedures [4][9]. Group 2: Financial Performance - ST Lifan has reported inflated revenues and costs for three consecutive years, leading to severe violations of securities laws [9]. - The company has consistently incurred losses, with total revenue reported at 2.03 billion yuan for the latest quarter, showing a year-on-year decrease of 0.44% [12]. - The net profit for the latest quarter was -620 million yuan, reflecting a year-on-year decline of 20.64% [12]. Group 3: Stock Market Impact - ST Lifan's stock will be suspended from trading starting December 1 and will resume trading with a delisting risk warning on December 2 [11]. - The stock price is subject to a daily fluctuation limit of 20% after the delisting risk warning is implemented [11]. - As of November 28, ST Lifan's stock price was 3.36 yuan per share, with a total market capitalization of 2.2 billion yuan [13]. Group 4: Shareholder Information - As of October 20, ST Lifan had over 30,000 shareholders, indicating a significant retail investor base [15]. - The number of shareholders has seen a slight decline, with a decrease of 58 accounts reported in the latest period [16].

人民财讯11月28日电，ST立方(300344)11月28日公告，公司收到安徽证监局的《行政处罚及市场禁入事 先告知书》，认定公司通过开展代理业务虚增营业收入、营业成本，开展融资性贸易虚增营业收入、营 业成本，开展虚假贸易虚增营业收入、营业成本、利润总额，根据《告知书》认定的事实，公司股票可 能被实施重大违法强制退市。公司股票于2025年12月1日起停牌，并于2025年12月2日(星期二)起复牌。 自复牌之日起，公司股票被实施退市风险警示。实施退市风险警示后公司股票在风险警示板交易，股票 价格的日涨跌幅限制为20%。 ...

据证监会官网，经查，2021—2023年，ST立方通过开展代理业务、融资性贸易、虚假贸易等方式，累计虚增收入6.38亿元、成本6.28亿元。其中，2021年收 入、成本分别虚增2.8亿元、2.77亿元，2022年收入、成本分别虚增3.12亿元、3.05亿元，2023年收入、成本分别虚增0.46亿元、0.45亿元。ST立方连续三年 虚增收入和成本，严重违反证券法律法规，安徽证监局拟对ST立方处以1000万元罚款，对汪逸等10名责任人合计罚款3000万元。ST立方涉嫌触及重大违法 强制退市情形，深交所将依法启动退市程序。 同日晚间，ST立方披露公告称，公司股票于12月1日起停牌，并于12月2日起复牌。自复牌之日起，公司股票被实施退市风险警示。公司股票简称由"ST立 方"变更为"*ST立方"。如根据正式的处罚决定书结论，公司触及重大违法强制退市情形，公司股票将被终止上市。 投融资专家许小恒对北京商报记者表示，中介机构是资本市场治理的重要力量，发挥着专业把关的积极作用，其执业质量直接关系市场健康运行。 | 序号 | | | | 南计单位 | | | --- | --- | --- | --- | --- | --- ...

Core Viewpoint - ST Lifan is facing severe financial fraud allegations, which may lead to its delisting from the stock market due to continuous financial misconduct from 2021 to 2023 [2][5][10]. Financial Misconduct - From 2021 to 2023, ST Lifan inflated its revenue by a total of 638 million yuan and costs by 628 million yuan through various fraudulent activities [10]. - The breakdown of inflated figures includes: - 2021: Revenue inflated by 280 million yuan, costs inflated by 277 million yuan - 2022: Revenue inflated by 312 million yuan, costs inflated by 305 million yuan - 2023: Revenue inflated by 46 million yuan, costs inflated by 45 million yuan [10]. Regulatory Actions - The Anhui Securities Regulatory Bureau plans to impose a total fine of 40 million yuan on ST Lifan and related responsible individuals due to the financial fraud [5]. - ST Lifan has been warned and fined 10 million yuan, while 10 responsible individuals, including the chairman and general manager, face a combined fine of 30 million yuan and a 10-year market ban [10]. - The case involving the accounting firm associated with ST Lifan is under formal investigation for failing to fulfill its duties [10]. Delisting Risk - ST Lifan is at risk of being forcibly delisted due to serious violations of securities laws, with the Shenzhen Stock Exchange initiating delisting procedures [5][12]. - The company's stock will be suspended from trading starting December 1 and will be subject to delisting risk warnings upon resumption [12]. Financial Performance - ST Lifan has reported continuous losses over the years, with a recent financial summary indicating a total revenue of 2.03 billion yuan and a net loss of 620 million yuan for the latest reporting period [14]. - The company has seen a decline in its stock price, closing at 3.36 yuan per share, with a total market capitalization of 2.2 billion yuan as of November 28 [15]. Shareholder Information - As of October 20, ST Lifan had over 30,000 shareholders, with a slight decrease in the number of shareholders noted in recent periods [16][17].

证监会11月28日消息， 近日，证监会对上市公司立方数科股份有限公司（简称立方数科）涉嫌定期报 告财务数据存在虚假记载作出行政处罚及市场禁入事先告知。 经查，2021年至2023年，立方数科通过开展代理业务、融资性贸易、虚假贸易等方式，累计虚增收入 6.38亿元、成本6.28亿元。立方数科连续三年虚增收入和成本，严重违反证券法律法规，安徽证监局拟 对立方数科处以1000万元罚款，对汪逸等10名责任人合计罚款3000万元。立方数科涉嫌触及重大违法强 制退市情形，深交所将依法启动退市程序。 同时，证监会决定对本案所涉会计师事务所执业行为正式立案调查，涉嫌未能勤勉尽责的将依法严惩。 对于相关违法行为可能涉及的证券犯罪问题线索，证监会将坚持应移尽移的工作原则，依法依规移送公 安机关。 此案是首例上市公司领罚单，中介机构被同步立案的典型，体现了监管部门打击财务造假"追首 恶"与"打帮凶"并重的导向，标志着全方位、立体式的综合惩防体系进一步走向深入。 立方数科或是今年第14家因财务造假而涉嫌触及重大违法强制退市的公司，年内触及重大违法强制退市 的公司数量创历年新高。这一变化源于退市新规对财务造假退市标准的调整，也源于严监 ...

Core Viewpoint - The article highlights the severe consequences faced by ST Lifan due to long-term systematic financial fraud, leading to administrative penalties and the initiation of delisting procedures by the Shenzhen Stock Exchange [1][2]. Financial Misconduct - ST Lifan has inflated its revenue by 638 million yuan and costs by 628 million yuan from 2021 to 2023 through various fraudulent activities [2]. - The inflated figures for each year are as follows: 2021 saw revenue and costs inflated by 280 million yuan and 277 million yuan respectively; 2022 saw 312 million yuan and 305 million yuan; and 2023 saw 46 million yuan and 45 million yuan [2]. - The company’s financial reports for 2021 and 2022 contained false records amounting to 591.58 million yuan, which constituted 50.91% of the total reported revenue for those years [2]. Regulatory Actions - The China Securities Regulatory Commission (CSRC) has proposed a fine of 10 million yuan against ST Lifan and a total of 30 million yuan against 10 responsible individuals, including a 10-year market ban for three senior executives [1][3]. - The Shenzhen Stock Exchange will initiate delisting procedures due to the company’s significant violations [1][2]. Corporate Governance Issues - The fraudulent activities were facilitated by key executives, including the chairman and general manager, who neglected their duties and allowed the misconduct to occur [3]. - The company’s internal controls and oversight mechanisms were ineffective, as evidenced by the systemic fraud despite multiple individuals signing declarations of accuracy and completeness [4]. Legal and Market Implications - The company faces additional legal challenges, including a contract dispute linked to a criminal investigation, which may impact its future profitability [4]. - A significant shareholder's stock will undergo a second judicial auction, although it is noted that this will not change the company's control [4]. Investor Protection and Market Confidence - Recent cases in China indicate a shift towards systematic investor protection mechanisms, with collective redress becoming more prevalent [5]. - However, the article emphasizes that post-fraud compensation cannot fully restore market confidence or mitigate the liquidity loss from delisting [6]. - There is a call for stronger governance measures to ensure compliance and accountability among executives, as well as enhanced audit responsibilities for accounting firms [6].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has imposed administrative penalties and market bans on Lifan Shuke Co., Ltd. for falsifying financial data in its periodic reports from 2021 to 2023, leading to significant financial discrepancies and potential delisting from the Shenzhen Stock Exchange [1][2]. Summary by Sections Financial Misconduct - Lifan Shuke inflated its revenue by a total of 638 million yuan and costs by 628 million yuan from 2021 to 2023 through various fraudulent activities, including agency business and fictitious trades [1]. - The breakdown of inflated figures includes 280 million yuan in revenue and 277 million yuan in costs for 2021, 312 million yuan in revenue and 305 million yuan in costs for 2022, and 46 million yuan in revenue and 45 million yuan in costs for 2023 [1]. Regulatory Actions - The CSRC plans to impose a fine of 10 million yuan on Lifan Shuke and a total of 30 million yuan in fines on 10 responsible individuals, including the company's former chairman and executives [1]. - The company is facing potential delisting due to serious violations of securities laws, with the Shenzhen Stock Exchange initiating delisting procedures [1]. Individual Accountability - Key executives, including former chairman Wang Yi and general manager Yu Kebai, are facing a 10-year ban from the securities market due to their roles in the misconduct [2]. - The CSRC has also announced that it will investigate the accounting firm involved for failing to perform due diligence [1][2]. Company Profile - Lifan Shuke is a digital technology cloud service provider focused on new digital infrastructure, with a total market capitalization of 2.1 billion yuan [2].

Group 1 - Jianbang Co., Ltd. plans to repurchase shares using self-owned funds between 15 million and 30 million yuan, with a maximum price of 38 yuan per share [1] - Yatong Precision Engineering's investment in a private equity fund has been terminated due to failure to complete the agreed investment, leading to the fund's dissolution [1] - China Storage Co., Ltd. intends to invest 1.129 billion yuan in the Sanjiang Port project, with its wholly-owned subsidiary contributing 500 million yuan to establish a project company [2] Group 2 - Guangxin Co., Ltd. plans to inject assets worth 4.383 billion yuan into its wholly-owned subsidiary, increasing its registered capital from 10 million to 20 million yuan [3] - Jiangxin Home plans to use up to 3 billion yuan of idle self-owned funds for cash management in low-risk financial products [4] - Huangshan Tourism intends to lease part of the Huangshan scenic area for 1.27 billion yuan over a 10-year period [5] Group 3 - Jilin Expressway's general manager has resigned due to work adjustments [6] - Guoyao Modern's subsidiary has received a drug registration certificate for hydromorphone hydrochloride injection, suitable for pain management [8] - Hangya Technology plans to invest up to 70 million USD to establish subsidiaries in Singapore and Malaysia [10] Group 4 - ST Sailong's subsidiary has received approval for the listing of two chemical raw materials [11] - Shanghai Pharmaceuticals' tramadol hydrochloride injection has passed the consistency evaluation for generic drugs [12] - Yubang Electric has obtained a laboratory accreditation certificate from CNAS, indicating its testing capabilities [14] Group 5 - ST Lifang's stock will be subject to delisting risk warning starting December 1 due to administrative penalties [15] - Zhejiang Longsheng is investing 200 million yuan in a private equity partnership focused on high-potential enterprises [15] - Huayang Co., Ltd.'s subsidiary has obtained safety production permits, allowing it to commence production [16] Group 6 - Xujie Electric has won a bid for a State Grid project worth 1.518 billion yuan [17] - Pinggao Electric and its subsidiaries have collectively won a State Grid project worth approximately 773 million yuan [17] - ST Lanhua's subsidiary has entered the trial production phase for a juice beverage project with a total investment of up to 65 million yuan [18] Group 7 - Huakong Saige has terminated its stock issuance plan due to various considerations [19] - Yatong Co., Ltd. plans to invest 36 million yuan to establish a joint venture in renewable energy [20] - Warner Pharmaceuticals has received a drug registration certificate for a new inhalation solution for COPD patients [21] Group 8 - Demais has raised the upper limit for its share repurchase price to 45 yuan per share [22] - China West Electric's subsidiaries have collectively won a State Grid procurement project worth approximately 2.98 billion yuan [22] - Changan Automobile's joint venture has submitted a listing application to the Hong Kong Stock Exchange [23] Group 9 - Yinlun Co., Ltd. plans to invest approximately 133 million yuan to acquire a controlling stake in Shenzhen Deep Blue Electronics [24] - Zhongfu Information intends to increase its wholly-owned subsidiary's capital by 380 million yuan [24] - Financial Street's major shareholder has reduced its stake by 0.25% [25] Group 10 - Audiwei has formally submitted an application for H-share listing [26] - Zhongcai Technology's private placement application has been accepted by the Shenzhen Stock Exchange [27] - Haowei Group's subsidiary plans to invest 200 million yuan in a private equity fund focused on semiconductor investments [28] Group 11 - Jinkai New Energy is planning to transfer 51% of its subsidiary's equity to introduce strategic investors [31] - Huafeng Technology has reduced its fundraising target for a private placement to no more than 972 million yuan [32] - Mindray Medical's chairman plans to increase his stake in the company by 200 million yuan [33] Group 12 - Zhongman Petroleum's shareholders plan to reduce their holdings by up to 3% [35] - Innovation New Materials' shareholder intends to reduce their stake by up to 1% [37] - Guangdong Construction has signed a framework agreement to establish a quality testing base in Linzhi Economic Development Zone [39]

公司股票于2025年12月1日(星期一)开市起停牌一天，于2025年12月2日(星期二)开市起复牌。自复牌之 日起，公司股票被实施退市风险警示。 ST立方（300344）(300344.SZ)公告，公司于2025年11月28日收到中国证券监督管理委员会安徽监管局 《行政处罚及市场禁入事先告知书》，认定公司通过开展代理业务虚增营业收入、营业成本，开展融资 性贸易虚增营业收入、营业成本，开展虚假贸易虚增营业收入、营业成本、利润总额。 根据《告知书》认定的事实，公司2021年、2022年、2023年年度报告存在虚假记载，同时，2021、2022 年虚假记载的营业收入金额合计达5.92亿元，且占该2年披露的年度营业收入合计金额的50.91%;公司可 能触及《深圳证券交易所创业板股票上市规则》第10.5.2条第(六)项的"根据中国证监会行政处罚决定载 明的事实，公司披露的年度报告财务指标连续三年存在虚假记载，前述财务指标包括营业收入、利润总 额、净利润、资产负债表中的资产或者负债科目"、《深圳证券交易所创业板股票上市规则》第10.5.2条 第(七)项规定"根据中国证监会行政处罚决定载明的事实，公司披露的营业收入连续两年 ...